Price
$23.32+12.39%Social Signal Score
Analyst Ratings
11 analystsRevenue
$108.21MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Ying Du
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1,784
- Beta
- 0.83
- Country
- CN
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -0.39
Financials
Revenue
$108.21M+83489.3%Net Income
$-46.14MEBITDA
$-46.43MFree Cash Flow
$-58.81MEPS (diluted)
$-0.40Shares Outstanding (diluted)
112.34M+11558.7%Operating Expenses
$119.88MCash & Debt
$559.66MReturn of Capital
$0.00Revenue by Segment (annual)
$334.53MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $460.16M | $-175.54M | $-1.60 |
| 2024 | $398.99M | $-257.10M | $-2.60 |
| 2023 | $266.72M | $-334.62M | $-34.60 |
| 2022 | $215.04M | $-443.29M | $-46.30 |
| 2021 | $144.31M | $-704.47M | $-75.80 |
| 2020 | $48.96M | $-268.90M | $-34.60 |
| 2019 | $12.98M | $-195.07M | $-30.30 |
| 2018 | $129.5K | $-139.07M | $-26.40 |
| 2017 | $0.00 | $-50.38M | $-23.20 |
| 2016 | $0.00 | $-37.51M | $-39.70 |
| 2015 | $0.00 | $-18.02M | $-20.70 |
Valuation
ZLABhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
70+40.00%Social Signal Score
Mentions (14)
- Newsseekingalpha.com·6d ago·Positive
Zai Lab: Tarlatamab's First-Line Win Makes Zoci The DLL3 Partner Of Choice Zai Lab looks underappreciated as the wholly owned developer of zoci, a potential DLL3 treatment backbone, rather than merely a China distributor. Amgen and Boehringer are funding zoci combination studies; first-line data showed an 81.8% response rate across 33 evaluable patients. I estimate roughly ten quarters of debt-adjusted cash runway at elevated trial spending, while management expects product revenue growth to ret
View source ↗ - Newsbusinesswire.com·9d ago·Neutral
Zai Lab Announces Participation in Investor Conferences in November 2026 SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company's senior management team will participate in the following investor conferences in November 2026: UBS Global Biopharma Conference Date: November 17, 2026 Event Format: 1-on-1 meetings only Location: London, UK Jefferies Global Healthcare Conference in London Date: November 18 and 19, 2026 Fire…
View source ↗ - Newsbenzinga.com·9d ago·Neutral
Zai Lab Advances Atopic Dermatitis Candidate Toward Potential Quarterly Maintenance Dosing Zai Lab Limited (NASDAQ:ZLAB) reported preliminary results from the first-in-human portion of its global Phase 1/1b clinical trial evaluating ZL-1503, an investigational bispecific antibody for moderate-to-severe atopic dermatitis.
View source ↗ - Newsseekingalpha.com·9d ago·Positive
Zai Lab Limited (ZLAB) Discusses ZL-1503 Phase 1 Data and Atopic Dermatitis Development Plans Transcript Zai Lab Limited (ZLAB) Discusses ZL-1503 Phase 1 Data and Atopic Dermatitis Development Plans Transcript
View source ↗ - Newsmarketbeat.com·16d ago·Negative
Zai Lab Q3 Earnings Call Highlights Zai Lab NASDAQ: ZLAB reported $108.2 million in third-quarter revenue and said it expects to return to year-over-year product revenue growth in 2027, while advancing its lead cancer drug candidate toward potential U.S. regulatory submissions next year.
View source ↗ - Newsseekingalpha.com·17d ago·Positive
Zai Lab Limited (ZLAB) Q3 2026 Earnings Call Transcript Zai Lab Limited (ZLAB) Q3 2026 Earnings Call Transcript
View source ↗ - Newsseekingalpha.com·30d ago·Positive
Zai Lab Limited (ZLAB) Discusses Phase 1 Study Results of DLL3-Targeted ADC ZL-1310 in Small Cell Lung Cancer Transcript Zai Lab Limited (ZLAB) Discusses Phase 1 Study Results of DLL3-Targeted ADC ZL-1310 in Small Cell Lung Cancer Transcript
View source ↗ - Newsmarketbeat.com·30d ago·Negative
Zai Lab's Zoci Shows 82% Response Rate in Early Lung Cancer Study Zai Lab NASDAQ: ZLAB presented early-stage data at the 2026 European Society for Medical Oncology meeting for zoci, its DLL3-targeted antibody-drug conjugate, in combination with atezolizumab, with or without carboplatin, for first-line extensive-stage small cell lung cancer.
View source ↗ - Newsbusinesswire.com·30d ago·Negative
…ability and Well-Tolerated Safety Profile in First-Line Extensive-Stage Small Cell Lung Cancer SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovation-driven, global biopharma company, today shared the first data from a global Phase 1b clinical trial evaluating zocilurtatug pelitecan (zoci, formerly ZL-1310) in combination with atezolizumab with and without carboplatin as first-line treatment for extensive-stage small cell lung cancer (ES-SCLC). Th…
View source ↗ - Newsbusinesswire.com·31d ago·Negative
Zai Lab Announces $250 Million Private Placement SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) an innovation-driven, global biopharma company, today announced that it has entered into a securities purchase agreement for the sale of 11,340,000 American Depositary Shares (“ADSs”), each representing ten ordinary shares of the Company, to certain investors in a private investment in public equity (“PIPE”) financing. The purchase price of each ADS is $22.04.…
View source ↗ - Newscnbc.com·87d ago·Neutral
Z.ai shares surge 8% after releasing new AI model running only on Chinese chips Z.ai's shares rose after the company launched a new AI model that it claimed runs only on Chinese chips. It's the latest indication of China's efforts to ramp up homegrown computing capability.
View source ↗ - Newsseekingalpha.com·95d ago·Negative
Zai Lab: Revenue Growth And Zoci's Upside Optionality ZLAB has grown from a Greater China licensing platform into a dual-engine biopharma. They have a growing proprietary global pipeline with KarXT and TIVDAK. And management expects product sales to stabilize during 2H2026. Zoci's SCLC and NEC activity looks promising, while their other partnered combo therapies could expand their indications across other treatments.
View source ↗ - Newsbusinesswire.com·97d ago·Positive
… Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis SHANGHAI & CAMBRIDGE, Mass. & AMSTERDAM--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) and argenx (Euronext & NASDAQ: ARGX), today announced positive topline results from the ALKIVIA Phase 3 study evaluating VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) in adults with autoimmune myositis. Study met its primary endpoint (p=0.0011) In the combined immune-mediated necrotizing myopathy (IMN…
View source ↗ - Newsmarketbeat.com·107d ago·Neutral
Zai Lab Q2 Earnings Call Highlights Zai Lab NASDAQ: ZLAB said its second-quarter net product revenue rose 11% sequentially to $105.8 million as the company continued to invest in a pipeline it expects to support a transition into a global biopharmaceutical business.
View source ↗
Earnings
Thu, Feb 25(in 3 months)
Consensus estimate $-0.52 per share
Typical surprise +10.0% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Nov 5$-0.41 vs $-0.59beat
- Thu, Aug 6$-0.46 vs $-0.68beat
- Thu, May 7$-0.46 vs $-0.53beat
- Thu, Feb 26$-0.46 vs $-0.44miss
- Thu, Nov 6$-0.33 vs $-0.28miss
- Thu, Aug 7$-0.37 vs $-0.37beat
Estimates and results for ZLAB via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ZLAB officers and directors.
- Bought
- $66k
- Sold
- $6.0m
2 trades
24 trades
- Gaynor Richardbought
- Chen Yajingsold
- Lis Williamsold
- Chen Yajingsold
- Gaynor Richardbought
- Du Yingsold
- Edmondson Frazor Titus Iiisold
- Du Yingsold
74 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in ZLAB.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
